Formulations That Meet Unmet Patient Needs

Mapi Pharma is a clinical-stage pharmaceutical company developing long acting depot injections with extended-release formulations of existing commercially successful products. In addition, the Company develops generic drugs that include complex Active Pharmaceutical Ingredients and finished dosage formulations. The company’s lead product, Glatiramer Acetate, is a monthly depot version of the active ingredient in Copaxone, a blockbuster medication for the treatment of multiple sclerosis which is currently given multiple times a week. With a greatly reduced and simplified treatment regimen, the company believes it can increase patient compliance and reduce treatment burden. The Company’s development portfolio consists of several advanced proprietary programs and product collaborations with leading pharma companies.

Leadership:

Investing partner / fund: